Jefferies initiates Allogene stock coverage with buy rating on cancer therapy potential

Financial services firm Jefferies initiated coverage of Allogene Therapeutics, a clinical-stage biotechnology company, with a 'Buy' rating in a research note published on Monday, citing the significant long-term potential of the company's 'off-the-shelf' allogeneic CAR-T cell therapies for treating cancer. The analysts set a price target of $10 per share for Allogene's stock, which represents a substantial upside from its current trading level. The initiation underscores a vote of confidence in the company's pipeline and its underlying technology platform. The coverage highlights Allogene's focus on developing allogeneic, or donor-derived, CAR-T therapies, which are manufactured from healthy donor cells rather than a patient's own. This approach aims to create a more scalable, readily available, and potentially less expensive alternative to the current standard of autologous CAR-T treatments, which are bespoke products created from an individual patient's cells. Jefferies' analysts believe this technology could address key limitations in the field, including manufacturing complexity and treatment delays. Allogene's lead product candidate, ALLO-501A, is currently in clinical trials for treating large B-cell lymphoma. The positive analyst outlook is based on the progress of this and other pipeline assets, as well as the broader market opportunity for allogeneic cell therapies. The initiation comes at a time of heightened investor interest in next-generation oncology treatments, positioning Allogene as a key player in the evolving immunotherapy landscape. The firm's assessment suggests that if successful, Allogene's platform could capture a meaningful share of the multi-billion dollar cancer therapy market.